AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

Date : 03/11/2019 @ 8:01PM
Source : PR Newswire (US)
Stock : AcelRX Pharmaceuticals Inc (ACRX)
Quote : 2.5  -0.02 (-0.79%) @ 5:00AM

AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart

1 Year : From Sep 2018 to Sep 2019

Click Here for more AcelRX Pharmaceuticals Charts.

REDWOOD CITY, Calif., March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be presenting at the Oppenheimer 29th Annual Healthcare Conference to be held March 19 – 20. AcelRx management will provide an overview of the business and company updates during the live presentation and will be available for one-on-one investor meetings. 

Details of the event are as follows:

Oppenheimer 29th Annual Healthcare Conference
Date: Wednesday, March 20, 2019
Location: Westin Grand Central, New York, NY
Presentation Time: 2:45 pm ET (11:45 a.m. PT)

The conference presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com. 

Media Contacts:

Investor Contacts:

Theresa Dolge, Evoke

Raffi Asadorian, CFO, AcelRx

215-928-2748

investors@acelrx.com                   

theresa.dolge@evokegroup.com


Jessica Ross, Evoke

Brian Korb, Solebury Trout

215-928-2346

646-378-2923

jessica.ross@evokegroup.com

investors@acelrx.com 

 

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-oppenheimer--co-inc-29th-annual-healthcare-conference-300810254.html

SOURCE AcelRx Pharmaceuticals, Inc.

Copyright 2019 PR Newswire

Latest ACRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.